Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14451432 | 1.00 | PARP15 (0.50) | PARP15PARP10PARP2CARM1PRMT6 | |
| Hydrochloric Acid SCHEMBL5519191 | 0.98 | HTR2C (0.49) | PARP15PARP10PARP2CARM1PRMT6 | |
| Hydrochloric Acid SCHEMBL5521261 | 0.98 | HTR2C (0.49) | PARP15PARP10PARP2CARM1PRMT6 | |
| SCHEMBL1990800 | 0.90 | TDP1 (0.57) | PARP15PARP10PARP2CARM1PRMT6 | |
| Hydrochloric Acid SCHEMBL3037711 | 0.83 | PARP15 (0.49) | PARP15PARP10PARP2CARM1PRMT6 | |
| Hydrochloric Acid SCHEMBL3037709 | 0.83 | PARP15 (0.49) | PARP15PARP10PARP2CARM1PRMT6 | |
| SCHEMBL11247511 | 0.82 | LTA4H (0.57) | PARP15PARP10PARP2CARM1PRMT6 | |
| SCHEMBL10533845 | 0.82 | PARP15 (0.56) | PARP15PARP10PARP2CARM1PRMT6 | |
| SCHEMBL8284721 | 0.81 | TAAR1 (0.52) | TAAR1 | |
| SCHEMBL8285615 | 0.81 | PARP15 (0.51) | PARP15PARP10PARP2HTR2CDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | PARP15 3115/4885PARP10 3349/4885PARP2 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.